Improving compliance and persistence with bisphosphonate therapy for osteoporosis

被引:69
作者
Emkey, RD
Ettinger, M
机构
[1] Radiant Res, Wyomissing, PA 19610 USA
[2] Reg Osteoporosis Ctr, Stuart, FL USA
关键词
bisphosphonates; compliance; osteoporosis; persistence;
D O I
10.1016/j.amjmed.2005.12.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The successful treatment of patients at increased risk for fracture requires proper diagnosis and the development of a treatment plan that permits the patient to take medications in accordance with dosing guidelines and on the correct schedule. Data indicate that patients with osteoporosis who have good long-term medication compliance experience substantially lower risk of fracture. Persistence with therapy also correlates with better bone mineral density and improved suppression of bone turnover markers. Although bisphosphonates are the most potent currently approved antiresorptive agents, they have special dosing issues that can have a negative impact on long-term persistence. The inconvenience and complexity of some dosing requirements; the potential for adverse effects, especially when dosing recommendations are not followed; and very low absorption rates - even under ideal conditions - all contribute to poor outcomes. Extension of the dosing interval from a once-daily to a once-weekly regimen is associated with comparable efficacy, theoretically may improve gastrointestinal safety, and is associated with substantial improvement in persistence with therapy. However, compliance with weekly regimens remains suboptimal. Monthly dosing of ibandronate, a bisphosphonate, was recently approved by the US Food and Drug Administration (FDA). Although extending the dosing interval may improve compliance and persistence with bisphosphonate therapy, it is important to recognize that missed doses or improper dosing may have greater consequences with extended dosing intervals. This article highlights the importance of educating patients about their diagnosis and long-term treatment plan, including the importance of persistence with therapy and compliance with dosing recommendations. (C) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:18S / 24S
页数:7
相关论文
共 31 条
[1]   Low frequency of treatment of osteoporosis among postmenopausal women following a fracture [J].
Andrade, SE ;
Majumdar, SR ;
Chan, KA ;
Buist, DSM ;
Go, AS ;
Goodman, M ;
Smith, DH ;
Platt, R ;
Gurwitz, JH .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (17) :2052-2057
[2]  
*AV PHARM INC, 2004, ACT RIS SOD TABL PRE
[3]  
Becker Stephen L, 2002, MedGenMed, V4, P21
[4]   Nonadherence in asthmatic patients: is there a solution to the problem? [J].
Bender, B ;
Milgrom, H ;
Rand, C .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1997, 79 (03) :177-185
[5]   The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis [J].
Brown, JP ;
Kendler, DL ;
McClung, MR ;
Emkey, RD ;
Adachi, JD ;
Bolognese, MA ;
Li, Z ;
Balske, A ;
Lindsay, R .
CALCIFIED TISSUE INTERNATIONAL, 2002, 71 (02) :103-111
[6]   The impact of compliance with osteoporosis therapy on fracture rates in actual practice [J].
Caro, JJ ;
Ishak, KJ ;
Huybrechts, KF ;
Raggio, G ;
Naujoks, C .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) :1003-1008
[7]   A systematic review of the associations between dose regimens and medication compliance [J].
Claxton, AJ ;
Cramer, J ;
Pierce, C .
CLINICAL THERAPEUTICS, 2001, 23 (08) :1296-1310
[8]   The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled [J].
Clowes, JA ;
Peel, NFA ;
Eastell, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (03) :1117-1123
[9]  
Cox Emily R, 2002, J Manag Care Pharm, V8, P360
[10]   Medicare beneficiaries' management of capped prescription benefits [J].
Cox, ER ;
Jernigan, C ;
Coons, SJ ;
Draugalis, JR .
MEDICAL CARE, 2001, 39 (03) :296-301